Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

NRBO Financial Statements and Analysis

NASDAQ : NRBO

NeuroBo Pharmaceuticals, Inc.

$2.36
N/A-
At Close 4:00 PM
Not Actively Trading
66.16
BESG ScoreESG Rating

NRBO FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

NRBO Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue0004.00K0
cost of revenue06.00K4.00K4.00K1.00K
gross profit0-6.00K-4.00K0-1.00K
gross profit ratio00000
research and development expenses4.517M8.074M4.904M3.861M2.292M
general and administrative expenses1.742M2.01M1.977M1.802M1.601M
selling and marketing expenses0-6.00K-4.00K00
selling general and administrative expenses1.742M2.004M1.973M1.802M1.601M
other expenses0004.00K0
operating expenses6.259M10.078M6.877M5.663M3.893M
cost and expenses6.259M10.084M6.881M5.667M3.893M
interest income310.00K164.00K237.00K299.00K162.00K
interest expense00000
depreciation and amortization5.00K6.00K4.00K4.00K1.00K
ebitda-6.254M-10.078M-6.877M-5.663M-3.893M
ebitda ratio000-1.416K0
operating income-6.259M-10.084M-6.881M-5.667M-3.893M
operating income ratio000-1.417K0
total other income expenses net607.00K31.00K167.00K353.00K75.00K
income before tax-5.652M-10.053M-6.714M-5.314M-3.818M
income before tax ratio000-1.329K0
income tax expense00-39.276K0-1.00K
net income-5.652M-10.053M-6.714M-5.314M-3.818M
net income ratio000-1.329K0
eps-0.55-1.85-1.32-1.05-0.75
eps diluted-0.55-1.85-1.32-1.05-0.75
weighted average shs out10.214M5.429M5.089M5.08M5.076M
weighted average shs out dil10.214M5.429M5.089M5.08M5.076M
Graph

NRBO Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents21.669M27.934M15.988M22.435M25.837M
short term investments0111.00K000
cash and short term investments21.669M27.934M15.988M22.435M25.837M
net receivables0073.00K00
inventory00000
other current assets266.00K583.00K703.00K77.00K308.00K
total current assets21.935M28.517M16.764M22.512M26.145M
property plant equipment net190.00K213.00K233.00K248.00K259.00K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets21.00K21.00K21.00K20.999K21.00K
total non current assets211.00K234.00K254.00K268.999K280.00K
other assets0001.000
total assets22.146M28.751M17.018M22.781M26.425M
account payables1.017M2.632M2.079M821.00K1.981M
short term debt75.00K144.00K70.00K67.00K65.00K
tax payables00000
deferred revenue00001.614M
other current liabilities8.022M6.935M4.676M5.072M1.062M
total current liabilities9.114M9.711M6.825M5.96M4.722M
long term debt79.00K98.00K117.00K136.00K153.00K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities79.00K97.999K117.00K136.00K153.00K
other liabilities01.00000
capital lease obligations154.00K98.00K117.00K136.00K218.00K
total liabilities9.193M9.809M6.942M6.096M4.875M
preferred stock00000
common stock9.00K8.00K5.00K5.00K38.00K
retained earnings-130.684M-125.032M-114.979M-108.265M-102.951M
accumulated other comprehensive income loss00000
other total stockholders equity143.628M143.966M125.05M124.945M124.463M
total stockholders equity12.953M18.942M10.076M16.685M21.55M
total equity12.953M18.942M10.076M16.685M21.55M
total liabilities and stockholders equity22.146M28.751M17.018M22.781M26.425M
minority interest00000
total investments0111.00K000
total debt154.00K170.00K187.00K203.00K218.00K
net debt-21.515M-27.764M-15.801M-22.232M-25.619M
Graph

NRBO Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax000-1.268M0
stock based compensation243.895K134.00K105.00100.00K172.00K
change in working capital-2.621M2.529M92.00K1.875M739.00K
accounts receivables00000
inventory00000
accounts payables-1.374M138.00K1.258M-1.16M1.013M
other working capital-1.225M2.391M-1.166M3.035M-274.00K
other non cash items2.435M141.00K-1.074M1.21M92.00K
net cash provided by operating activities-5.589M-7.251M-6.442M-3.393M-2.814M
investments in property plant and equipment0-3.00K-5.00K-9.00K-37.00K
acquisitions net00000
purchases of investments19.998M0000
sales maturities of investments00000
other investing activites00000
net cash used for investing activites19.998M-3.00K-5.00K-9.00K-37.00K
debt repayment00000
common stock issued-19.159M19.20M000
common stock repurchased00000
dividends paid00000
other financing activites18.483M19.20M000
net cash used provided by financing activities-676.00K19.20M000
effect of forex changes on cash00000
net change in cash-6.265M11.946M-6.447M-3.402M-2.851M
cash at end of period21.669M27.934M15.988M22.435M25.837M
cash at beginning of period27.934M15.988M22.435M25.837M28.688M
operating cashflow-5.589M-7.251M-6.442M-3.393M-2.814M
capital expenditure0-3.00K-5.00K-9.00K-37.00K
free cash flow-5.589M-7.254M-6.447M-3.402M-2.851M
Graph

Frequently Asked Questions

How did NeuroBo Pharmaceuticals, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, NRBO generated $0.00 in revenue last quarter, while its costs came in at $0.00.

Last quarter, how much Gross Profit did NeuroBo Pharmaceuticals, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. NeuroBo Pharmaceuticals, Inc. reported a $0.00 Gross Profit for the quarter ended Sep 30, 2024.

Have NRBO's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. NRBO incurred $6.26M worth of Operating Expenses, while it generated -$6.26M worth of Operating Income.

How much Net Income has NRBO posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from NeuroBo Pharmaceuticals, Inc., the company generated -$5.65M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did NeuroBo Pharmaceuticals, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to NeuroBo Pharmaceuticals, Inc. as of the end of the last quarter was $21.67M.

What are NRBO's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, NRBO had Total Net Receivables of $0.00.

In terms of Total Assets and Current Assets, where did NeuroBo Pharmaceuticals, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of NRBO were $21.94M, while the Total Assets stand at $22.15M.

As of the last quarter, how much Total Debt did NeuroBo Pharmaceuticals, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of NRBO's debt was $154.00K at the end of the last quarter.

What were NRBO's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, NRBO reported total liabilities of $9.19M.

How much did NRBO's Working Capital change over the last quarter?

Working Capital Change for NRBO was -$2.62M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

NRBO generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. NRBO generated -$5.59M of Cash from Operating Activities during its recently reported quarter.

What was NRBO's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. NRBO reported a -$6.27M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph